Combination immunotherapy treatment effective before lung cancer surgery
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers from Â鶹ӳ» MD Anderson Cancer Center.Â
The findings, published today in Cancer Discovery, were first presented at the American Association for Cancer Research...
MD Anderson Research Highlights for April 13, 2022
Â鶹ӳ» MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...